Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shandong Xinhua Pharmaceutical Co Ltd Comments On H1 2013 Earnings Guidance


Friday, 12 Jul 2013 04:19am EDT 

Shandong Xinhua Pharmaceutical Co Ltd announced that for the first half of 2013, it expects decrease in the net profit attributable to the shareholders to be recorded as compared to that for the corresponding period in 2012. Based on the information available to the Company immediately preceding the release of this announcement, such estimated decrease in the profit attributable to the Shareholders is mainly attributable to factors such as the formation of fixed assets in the new park area resulting in an increase in depreciation charges, an increase in costs caused by the fluctuating raw material and power consumption during the initial production stage of production lines, an increase in management costs as more resources have been allocated to environmental protection, a foreign exchange loss caused by the appreciation of the Renminbi, an increase in financial expenses due to increased borrowings and an increase in expenses caused by increased investment in the research and development of new products. 

Company Quote

4.11
0.16 +4.05%
11 Jul 2014